JP2020504078A5 - - Google Patents

Download PDF

Info

Publication number
JP2020504078A5
JP2020504078A5 JP2019523865A JP2019523865A JP2020504078A5 JP 2020504078 A5 JP2020504078 A5 JP 2020504078A5 JP 2019523865 A JP2019523865 A JP 2019523865A JP 2019523865 A JP2019523865 A JP 2019523865A JP 2020504078 A5 JP2020504078 A5 JP 2020504078A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019523865A
Other languages
English (en)
Japanese (ja)
Other versions
JP7042816B2 (ja
JP2020504078A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/060690 external-priority patent/WO2018089532A1/en
Publication of JP2020504078A publication Critical patent/JP2020504078A/ja
Publication of JP2020504078A5 publication Critical patent/JP2020504078A5/ja
Priority to JP2021206917A priority Critical patent/JP2022031969A/ja
Application granted granted Critical
Publication of JP7042816B2 publication Critical patent/JP7042816B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019523865A 2016-11-08 2017-11-08 レプチン受容体をアンタゴナイズする抗原結合性タンパク質 Active JP7042816B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021206917A JP2022031969A (ja) 2016-11-08 2021-12-21 レプチン受容体をアンタゴナイズする抗原結合性タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419062P 2016-11-08 2016-11-08
US62/419,062 2016-11-08
PCT/US2017/060690 WO2018089532A1 (en) 2016-11-08 2017-11-08 Antigen-binding proteins that antagonize leptin receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021206917A Division JP2022031969A (ja) 2016-11-08 2021-12-21 レプチン受容体をアンタゴナイズする抗原結合性タンパク質

Publications (3)

Publication Number Publication Date
JP2020504078A JP2020504078A (ja) 2020-02-06
JP2020504078A5 true JP2020504078A5 (https=) 2020-12-10
JP7042816B2 JP7042816B2 (ja) 2022-03-28

Family

ID=60409473

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019523865A Active JP7042816B2 (ja) 2016-11-08 2017-11-08 レプチン受容体をアンタゴナイズする抗原結合性タンパク質
JP2021206917A Pending JP2022031969A (ja) 2016-11-08 2021-12-21 レプチン受容体をアンタゴナイズする抗原結合性タンパク質
JP2023076083A Active JP7611292B2 (ja) 2016-11-08 2023-05-02 レプチン受容体をアンタゴナイズする抗原結合性タンパク質
JP2024088870A Pending JP2024109952A (ja) 2016-11-08 2024-05-31 レプチン受容体をアンタゴナイズする抗原結合性タンパク質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021206917A Pending JP2022031969A (ja) 2016-11-08 2021-12-21 レプチン受容体をアンタゴナイズする抗原結合性タンパク質
JP2023076083A Active JP7611292B2 (ja) 2016-11-08 2023-05-02 レプチン受容体をアンタゴナイズする抗原結合性タンパク質
JP2024088870A Pending JP2024109952A (ja) 2016-11-08 2024-05-31 レプチン受容体をアンタゴナイズする抗原結合性タンパク質

Country Status (29)

Country Link
US (3) US10550192B2 (https=)
EP (2) EP4613772A3 (https=)
JP (4) JP7042816B2 (https=)
KR (1) KR102563568B1 (https=)
CN (1) CN110167965A (https=)
AU (2) AU2017359439B2 (https=)
CA (1) CA3043365A1 (https=)
CL (3) CL2019001263A1 (https=)
CO (1) CO2019004672A2 (https=)
DK (1) DK3538554T3 (https=)
EA (1) EA201991075A1 (https=)
ES (1) ES3040144T3 (https=)
FI (1) FI3538554T3 (https=)
HR (1) HRP20251165T1 (https=)
HU (1) HUE073276T2 (https=)
IL (2) IL266426B (https=)
LT (1) LT3538554T (https=)
MA (1) MA45801B1 (https=)
MX (2) MX2019005397A (https=)
MY (2) MY191256A (https=)
PH (1) PH12019500988A1 (https=)
PL (1) PL3538554T3 (https=)
PT (1) PT3538554T (https=)
RS (1) RS67214B1 (https=)
SG (1) SG10201913470SA (https=)
SI (1) SI3538554T1 (https=)
SM (1) SMT202500327T1 (https=)
UA (1) UA127678C2 (https=)
WO (1) WO2018089532A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
US10550192B2 (en) 2016-11-08 2020-02-04 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
WO2019126071A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
DK3773713T3 (da) 2018-04-06 2025-08-18 Regeneron Pharma Leptinreceptoragonistantistof til anvendelse i forøgelse af knoglemasse hos et individ, der lider af metabolisk dysfunktion eller hypoleptinæmI
WO2020016160A1 (en) * 2018-07-16 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat neurological diseases
KR20210104744A (ko) 2018-12-18 2021-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
JP7783816B2 (ja) * 2020-07-17 2025-12-10 住友精化株式会社 吸収体
JP2023543409A (ja) * 2020-09-15 2023-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 疼痛に対するｌｅｐｒアゴニストの使用
CN118436632B (zh) * 2024-07-05 2024-08-30 四川大学华西第二医院 Teriflunomide在制备预防和/或治疗原发性纤毛不动综合征的药物中的用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US6977240B1 (en) * 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
ATE307887T1 (de) 1996-01-08 2005-11-15 Genentech Inc Ob-rezeptor und liganden
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
DK0892849T3 (da) 1996-01-23 2006-07-24 Indevus Pharmaceuticals Inc Fremgangsmåde til anvendelse af obese-genet og dets genprodukt til stimulering af hæmatopoietisk udvikling
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US5965521A (en) 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
FR2852397B1 (fr) 2003-03-10 2005-04-29 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.
ES2289235T3 (es) * 2003-08-21 2008-02-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Nuevo antagonista de leptina.
DE10353593A1 (de) * 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
CA2585549A1 (en) 2004-11-18 2006-05-26 Vib Vzw Novel type leptin receptor antagonist
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
WO2006116260A2 (en) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
MX2013009151A (es) 2011-02-10 2013-08-29 Roche Glycart Ag Inmunoterapia mejorada.
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EA035987B1 (ru) 2012-09-12 2020-09-09 Джензим Корпорейшн ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ АФФИННОСТЬЮ К Fc-ГАММА РЕЦЕПТОРАМ
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP2840892B1 (en) * 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
ES2831014T3 (es) 2014-02-18 2021-06-07 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de enfermedades mediadas por la vía de señalización del complejo NRP-1/OBR
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
US10550192B2 (en) 2016-11-08 2020-02-04 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor

Similar Documents

Publication Publication Date Title
JP2020504078A5 (https=)
JP2021508469A5 (https=)
JP2020528750A5 (https=)
FI3538554T3 (fi) Antigeeniä sitovia proteiineja, jotka antagonisoivat leptiinireseptoria
JP2021527431A5 (https=)
JP6608698B2 (ja) Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト
JP2020510422A5 (https=)
JP2019521098A5 (https=)
JP2020532965A (ja) 抗ｃｄ１３７分子及びその使用
JP2014500009A5 (https=)
WO2023206350A1 (en) Anti-ccr8 antibodies and uses thereof
JP2020501531A5 (https=)
JP2016519650A5 (https=)
JP2020514310A5 (https=)
JPWO2019129221A5 (https=)
JP2018506961A5 (https=)
JP2017535257A5 (https=)
JP2020529835A5 (https=)
JP2013539468A5 (https=)
JP2017519501A5 (https=)
JP2015529641A5 (https=)
JP2017532037A5 (https=)
JP2009529920A5 (https=)
KR20190028716A (ko) Pd-l1-특이적 항체 및 이를 사용하는 방법
JP2012504401A (ja) 抗ｃｘｃｒ４抗体および癌治療のためのそれらの使用